There are no Transcripts on SVON.
Wed, Jun. 25, 3:58 PM
Tue, Feb. 18, 7:20 AM
Dec. 30, 2013, 10:26 AM
- Senesco Technologies (SNTI +5.1%) agrees to terms and executes a non-binding LoI to merge with privately-held biotech firm Fabrus on an approximately 50-50 basis. A definitive agreement is expected in "early 2014."
- Fabrus aims to expand the impact of antibodies aimed at drug targets that are resistant to traditional antibody discovery methods. It has 2 collaborations with "large pharma and biotech companies" and an internal pipeline of antibodies targeting renal cell carcinoma and inflammation.
- CEO Leslie Browne: "Fabrus antibodies could complement our eIF5A gene regulatory platform, which has been shown to kill cancer cells, by directing nanoparticle-based therapeutics to the cells of interest."
- Making things more interesting: Phillip Frost's Frost Gamma Investments Trust, which recently made an investment in Senesco Technologies as detailed by SA Pro's John H. Ford, made an investment in Fabrus back in 2010.
Nov. 19, 2012, 4:39 PMSenesco Technologies (SNT) has received verbal notice from the NYSE of the exchange's decision to delist the company's common stock, effective prior to the open of trading on Wednesday, November 21. Upon delisting, the company intends to have its common stock quoted on the over-the-counter securities market. | Comment!
SVON vs. ETF Alternatives
The company's platform technology is based on the discovery that eIF5A (Factor 5A), a gene that is highly conserved from plants to people, has the ability to regulate programmed cell death, also known as apoptosis, and cell survival by controlling the expression of pro-apoptotic and... More
Other News & PR